替莫唑胺联合维利帕尼或安慰剂治疗复发敏感或难治性小细胞肺癌的随机双盲II期研究
该II期随机双盲研究纳入104例复发小细胞肺癌患者,比较替莫唑胺联合维利帕尼或安慰剂。两组4个月无进展生存率和中位总生存无显著差异,但联合维利帕尼组客观缓解率显著更高,且SLFN11阳性患者接受联合治疗的无进展生存和总生存显著延长。
要点
- 替莫唑胺联合维利帕尼组与安慰剂组4个月无进展生存率分别为36%和27%,差异无统计学意义(P=0.19)。
- 联合维利帕尼组客观缓解率显著高于安慰剂组(39% vs 14%,P=0.016)。
- SLFN11阳性肿瘤患者接受联合维利帕尼治疗的无进展生存和总生存显著延长。
核心结论
- 两组4个月无进展生存率和中位总生存无显著差异,但联合维利帕尼组客观缓解率显著改善。
- SLFN11表达与接受替莫唑胺联合维利帕尼治疗患者的无进展生存和总生存改善相关,提示其可能是小细胞肺癌PARP抑制剂敏感性的生物标志物。
研究设计与样本
- II期随机双盲研究,共纳入104例复发小细胞肺癌患者,按1:1随机分配接受口服维利帕尼或安慰剂40 mg每日两次(第1-7天)联合口服替莫唑胺150-200 mg/m2/天(第1-5天),28天为一周期,直至疾病进展、不可接受毒性或撤回知情同意。
- 主要终点为4个月无进展生存率改善;次要目标包括客观缓解率、总生存以及维利帕尼联合替莫唑胺的安全性和耐受性;探索性目标包括PARP-1和SLFN11免疫组化表达、MGMT启动子甲基化及循环肿瘤细胞定量。
主要发现
- 替莫唑胺联合维利帕尼组与联合安慰剂组4个月无进展生存率分别为36%和27%,差异无统计学意义(P=0.19)。
- 替莫唑胺联合维利帕尼组与联合安慰剂组中位总生存分别为8.2个月(95%CI 6.4-12.2个月)和7.0个月(95%CI 5.3-9.5个月),差异无统计学意义(P=0.50)。
- 替莫唑胺联合维利帕尼组客观缓解率显著高于联合安慰剂组(39% vs 14%,P=0.016)。
- 替莫唑胺联合维利帕尼组3/4级血小板减少和中性粒细胞减少发生率分别为50%和31%,安慰剂组分别为9%和7%。
- SLFN11阳性肿瘤患者接受替莫唑胺联合维利帕尼治疗的无进展生存(5.7个月 vs 3.6个月,P=0.009)和总生存(12.2个月 vs 7.5个月,P=0.014)显著延长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily, days 1 to 7, and oral TMZ 150 to 200 mg/m2/day, days 1 to 5, of a 28-day cycle until disease progression, unacceptable toxicity, or withdrawal of consent. Response was determined by imaging at weeks 4 and 8, and every 8 weeks thereafter. Improvement in PFS at 4 months was the primary end point. Secondary objectives included overall response rate (ORR), overall survival (OS), and safety and tolerability of veliparib with TMZ. Exploratory objectives included PARP-1 and SLFN11 immunohistochemical expression, MGMT promoter methylation, and circulating tumor cell quantification. Results No significant difference in 4-month PFS was noted between TMZ/veliparib (36%) and TMZ/placebo (27%; P = .19); median OS was also not improved significantly with TMZ/veliparib (8.2 months; 95% CI, 6.4 to 12.2 months; v 7.0 months; 95% CI, 5.3 to 9.5 months; P = .50). However, ORR was significantly higher in patients receiving TMZ/veliparib compared with TMZ/placebo (39% v 14%; P = .016). Grade 3/4 thrombocytopenia and neutropenia more commonly occurred with TMZ/veliparib: 50% versus 9% and 31% versus 7%, respectively. Significantly prolonged PFS (5.7 v 3.6 months; P = .009) and OS (12.2 v 7.5 months; P = .014) were observed in patients with SLFN11-positive tumors treated with TMZ/veliparib. Conclusion Four-month PFS and median OS did not differ between the two arms, whereas a significant improvement in ORR was observed with TMZ/veliparib. SLFN11 expression was associated with improved PFS and OS in patients receiving TMZ/veliparib, suggesting a promising biomarker of PARP-inhibitor sensitivity in SCLC.
引用
- Pietanza MC, Waqar SN, Krug LM, et al. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol. 2018. PMID: 29906251. doi:10.1200/JCO.2018.77.7672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。